In patients with T2D and DKD, ADA and KDIGO recommend the addition of a GLP-1 receptor agonist in those unable to achieve individualized glycemic goals despite first-line treatment with an SGLT2 inhibitor and metformin [23]. Here, GLP1R is linked to diabetic kidney disease.